Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05078034

HNFO With or Without Helmet NIV for Oxygenation Support in Acute Respiratory Failure Pilot RCT

This Randomized Control Trial will directly compare helmet non-invasive ventilation (NIV) combined with high flow nasal oxygen (HFNO) versus HFNO alone in patients with Acute Hypoxemic Respiratory Failure (AHRF).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Calgary, Calgary, Alberta, Canada

Loading trial locations.

About this study

This is a pilot multicentre, concealed, stratified, permuted block randomized controlled trial enrolling patients with AHRF who are admitted to the intensive care unit. Patients with imminent need for intubation, or a contraindication to study interventions will be excluded. Patients will be randomized to receive either (1) sessions of at least 12 hours per day of helmet NIV oxygen interspersed with HFNO or (2) HFNO alone over at least 2 calendar days. Participants will be followed to hospital discharge or 60 days, with an additional quality of life assessment via telephone interview 6 months after enrolment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Intensive care unit admission (orders written)
  • Age ≥18 years
  • Hypoxemic acute respiratory failure for at least 1 hour and still present at time of screening for eligibility (symptom onset during last 14 days) with the following:
  • Respiratory rate >21bpm or clinical evidence of increased work of breathing and
  • Documented Hypoxemia defined as any one of:

i. PaO2:FiO2 < 300 ii. If no arterial blood gas available, then SpO2:FiO2 < 315 iii. Oxygen saturation <98% on FiO2 >= 0.4 or higher by Venturi mask, TAVISH mask 10 Litres / minute, or any non-invasive oxygenation strategy

  • Not already intubated or with tracheostomy

Exclusion criteria

  • Already on HFNO or other non-invasive ventilation strategy at FiO2>=0.4 for the last 24 hours in the ICU.
  • Immediate need for intubation (e.g., inadequate airway protection or refractory hypoxemia or cardiopulmonary arrest, massive hemoptysis, etc)
  • Extubated in the ICU within past 72 hours
  • Clinician deems that face mask NIV is indicated to treat a primary diagnosis of hypercapnic respiratory failure or acute congestive heart failure
  • Known neuromuscular disease
  • Patients being transitioned to Palliative care or unlikely to survive more than 24 hours
  • ICU discharge is planned or anticipated on the day of screening
  • Previously enrolled in this trial
  • Trauma patients who remain in a cervical spine collar at the time of recruitment or who have upper limb/torso fractures that would preclude them from safe application of the helmet
  • Clinician decision that positive pressure to face and/or nasal pharynx is a contraindication (eg. Transphenoidal surgery, basal skull fracture etc.)

Treatment and study plan

Helmet Non-Invasive Ventilation (HNIV)

Device

HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.

Other names: HNIV

high flow nasal oxygen

Device

HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.

Other names: HFNO

Primary outcomes

  1. Recruitment Rates

    Time frame: 2 years

    Recruitment rate at different study sites

  2. Non-randomized Eligible Patients

    Time frame: 2 years

    Proportion of Eligible patients who are not randomized and reasons for this

  3. Adherence/Compliance to Oxygenation Strategy

    Time frame: 2 years

    Rate of adherence to the assigned oxygenation strategy (and crossover rates)

  4. Among patients requiring intubation in each group, the number who were intubated according to the pre-specified criteria

    Time frame: 2 years

    Adherence to pre-specified criteria for intubation in each group

  5. Time from ICU admission to randomization and initiation of treatment

    Time frame: 2 years

    Median time from ICU admission to randomization and initiation of the allocated treatment

Secondary outcomes

  1. Number of participants in each group who need endotracheal intubation

    Time frame: 28 and 60 days

    Need for endotracheal intubation after randomization

  2. Duration of invasive mechanical ventilation after randomization up to 28 and 60 days

    Time frame: 28 and 60 days

    Duration of invasive mechanical ventilation after randomization up to 28 and 60 days

  3. Duration of non-invasive respiratory support after randomization up to 28 and 60 days

    Time frame: 60 days

    Duration of non-invasive mechanical ventilation after randomization up to 60 days

  4. ICU length of stay

    Time frame: 28 days

    days of ICU up to 28 days after randomization

  5. All cause mortality

    Time frame: 60 days

    All cause mortality to 60 days

  6. COVID-19 infection after hospitalization

    Time frame: 28 days

    diagnosis of COVID-19

  7. Health related quality of life

    Time frame: 180 days

    Health related quality of life as measured by telephone using the European Quality of Life Five Dimension (EQ-5D) tool, where a score of 1 means the patient has no problems, and a score of 5 mean the patient has extreme problems in the 5 dimensions.

  8. Mortality at 180 days

    Time frame: 180 days

    Mortality to 180 days

  9. Activities of Daily Living

    Time frame: 180 days

    Katz Index of Independence in Activities of Daily Living (ADL) where a high of 6 means the patient can perform the activities fully independently, and a low of 0 means the patient is fully dependent and unable to perform activities without assistance.

  10. Ventilator-Free Days to day 28, analyzed as an ordinal variable, with death = 0 days

    Time frame: 28 days

    Ventilator-Free Days to day 28, analyzed as an ordinal variable, with death = 0 days

Sponsors and collaborators

Lead sponsor

Sunnybrook Health Sciences Centre

Other

Registry information

Official study title

High-flow Nasal Oxygen With or Without Helmet Non-invasive Ventilation for Oxygenation Support in Acute Respiratory Failure (the HONOUR Pilot Trial)

Acronym: HONOUR

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Oct 14, 2021
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.